Prognostic significance of early molecular response in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors

被引：3
|
作者：
Yeung, David T. [1 ,2 ]
Mauro, Michael J. [3 ]
机构：
[1] SA Pathol, Dept Haematol & Mol Pathol, Adelaide, SA, Australia
[2] Univ Adelaide, Sch Med, Discipline Med, Adelaide, SA, Australia
[3] Mem Sloan Kettering Canc Ctr, Myeloproliferat Neoplasms Program, New York, NY 10065 USA
来源：
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM | 2014年
基金：
英国医学研究理事会;
关键词：
BCR-ABL1 TRANSCRIPT LEVELS; FOLLOW-UP; IMATINIB; CML; PREDICT; DISCONTINUATION; RECOMMENDATIONS; DASATINIB; NILOTINIB; SURVIVAL;
D O I：
10.1182/asheducation-2014.1.240
中图分类号：
G40 [教育学];
学科分类号：
040101 ; 120403 ;
摘要：
A 55-year-old man presented with splenomegaly (10 cm below left costal margin) and leucocytosis (145 x 10(9)/L). Differential showed neutrophilia with increased basophils (2%), eosinophils (1.5%), and left shift including myeloblasts (3%). A diagnosis of chronic myeloid leukemia in chronic phase was established after marrow cytogenetics demonstrated the Philadelphia chromosome. Molecular studies showed a BCR-ABL1 qPCR result of 65% on the International Scale. Imatinib therapy at 400 mg daily was initiated due to patient preference, with achievement of complete hematological response after 4 weeks of therapy. BCR-ABL1 at 1 and 3 months after starting therapy was 37% and 13%, respectively (all reported on International Scale). Is this considered an adequate molecular response?
引用
收藏
页码：240 / 243
页数：4
相关论文
共 50 条
  • [21] STUDY OF THE MECHANISMS OF THROMBOGENESIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS
    Agula, S.
    Cuenca-Zamora, E.
    Lis, M. J.
    Noya-Pereira, M. S.
    Gutierrez-Garcia, V
    Garcia-Hernandez, M. C.
    Perez-Lopez, R.
    Fernandez, M. J.
    Palomera, L. R.
    Orti, G.
    Rosell, A.
    Vallansot, R.
    Angona-Figueras, A.
    Xicoy, B.
    Conesa, V
    Puerta, J. M.
    Perez-Encinas, M.
    Cortes, M.
    Hernandez-Boluda, J. C.
    Carreno, G.
    Mora, E.
    Giraldo, P.
    Vicente, V.
    Steegman, J. L.
    Ferrer-Marin, F.
    HAEMATOLOGICA, 2021, 106 (10) : 3 - 3
  • [22] Assessment of Cardiovascular Events in Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
    Pagnano, Katia B. B.
    Assuncao, Paola Morelato
    Zullli, Roberto
    Delamain, Marcia T.
    Duarte, Gislaine Oliveira
    Lorand-Metze, Irene
    De Souza, Carmino A., Sr.
    BLOOD, 2015, 126 (23)
  • [23] Prognostic Value of Clonal Evolution at the Time of Diagnosis in Patients with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors
    Alhuraiji, Ahmad
    Kantarjian, Hagop M.
    Jabbour, Elias J.
    Boddu, Prajwal Chaitanya
    Ravandi, Farhad
    Borthakur, Gautam
    DiNardo, Courtney D.
    Daver, Naval
    Kadia, Tapan M.
    Pemmaraju, Naveen
    Pierce, Sherry
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    BLOOD, 2016, 128 (22)
  • [24] PROGNOSTIC VALUE OF CYTOGENETIC ABNORMALITIES ASSOCIATED TO PHILADELPHIA CHROMOSOME IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA TREATED WITH TYROSINE KINASE INHIBITORS
    Jimenez-Rolando, M.
    Garcia-Gutierrez, J. V.
    Herrera, P.
    Lopez, J.
    Calbacho, M.
    Blanchard, M. J.
    Chinea, A.
    Delgado, I.
    Alonso, J. M.
    Velasco, D.
    Odriozola, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 533 - 533
  • [25] Impact of Molecular Response at Specific Timepoints in Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Second Generation Tyrosine Kinase Inhibitors
    Sasaki, Koji
    Kantarjian, Hagop M.
    Issa, Ghayas C.
    Garcia-Manero, Guillermo
    Kadia, Tapan M.
    Wierda, William G.
    Yilmaz, Musa
    DiNardo, Courtney D.
    Skinner, Jeffrey
    Khouri, Rita
    Pemmaraju, Naveen
    Nasnas, Patrice
    Dellasala, Sara E.
    Pierce, Sherry A.
    Cortes, Jorge E.
    Jabbour, Elias
    BLOOD, 2020, 136
  • [26] Tyrosine kinase inhibitors in chronic myeloid leukemia
    Sawyers, CL
    Druker, B
    CANCER JOURNAL FROM SCIENTIFIC AMERICAN, 1999, 5 (02): : 63 - 69
  • [27] Prospective Biochemical Analysis of Chronic Myeloid Leukemia Patients in Response to Tyrosine Kinase Inhibitors
    Arsalan, Hafiz Muhammad
    Arif, Amina
    Khan, Muhammad Khalil Ahmad
    PAKISTAN JOURNAL OF ZOOLOGY, 2023, 55 (05) : 2103 - 2111
  • [28] Response to Tyrosine Kinase Inhibitors in Real-World Patients With Chronic Myeloid Leukemia
    Szeto, Andy H.
    Bucci, Tyler
    Deal, Allison
    Zhu, Anqi
    Ahmad, Majd
    Cass, Amanda S.
    Sketch, Margaret R.
    Kemper, Ryan
    Zeidner, Joshua F.
    Foster, Matthew C.
    Muluneh, Benyam
    Crona, Daniel J.
    ANNALS OF PHARMACOTHERAPY, 2022, 56 (07) : 753 - 763
  • [29] Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors
    Rodia, R.
    Pani, F.
    Caocci, G.
    La Nasa, G.
    Simula, M. P.
    Mulas, O.
    Velluzzi, F.
    Loviselli, A.
    Mariotti, S.
    Boi, F.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2022, 45 (02) : 291 - 300
  • [30] Thyroid autoimmunity and hypothyroidism are associated with deep molecular response in patients with chronic myeloid leukemia on tyrosine kinase inhibitors
    R. Rodia
    F. Pani
    G. Caocci
    G. La Nasa
    M. P. Simula
    O. Mulas
    F. Velluzzi
    A. Loviselli
    S. Mariotti
    F. Boi
    Journal of Endocrinological Investigation, 2022, 45 : 291 - 300
12345